Trial Profile
Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy Versus Surgery Alone in Resectable Esophageal Squamous Cell Carcinoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II/III
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Nimotuzumab (Primary) ; Paclitaxel (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 16 Mar 2021 Status changed from suspended to withdrawn prior to enrolment.
- 16 Mar 2021 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 16 Mar 2021 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.